Co-Founder, Hoot HRT
Testosterone therapy raises hematocrit by stimulating red blood cell production. Most men tolerate this well, but when hematocrit climbs above 54 percent, the risk of blood clots increases. Hoot HRT monitors hematocrit at baseline, 6 weeks, 6 months, and every 6 months after that for every patient in Texas.
Most conversations about TRT side effects focus on mood changes, acne, or estrogen. What gets mentioned far less often is the one that shows up consistently in bloodwork across therapy: rising hematocrit. Hematocrit on TRT is one of the most predictable clinical concerns in testosterone therapy, and it is also one of the most manageable when someone is actually watching for it. The problem is not that TRT raises red cell counts. It is that many clinics are not checking.
Hematocrit is the percentage of your blood that is made up of red blood cells. A normal range for adult men runs roughly 40 to 50 percent. When it climbs above that range, blood becomes more viscous, thick blood, in plain terms, and the heart has to work harder to push it through vessels. Blood that moves more slowly and under more pressure is more likely to form clots in ways that carry real cardiovascular risk.
For most men, a modest rise from TRT is not a problem. The body adapts. But when hematocrit climbs above certain thresholds, the risk calculus changes. A number that starts at 46 and moves to 49 over six months is a different clinical picture from one that moves from 48 to 55. Understanding where you are and where you are heading is what separates careful hormone care from a model that refills prescriptions and sends patients on their way. The how it works page covers what a properly monitored evaluation looks like from the first visit forward.
Testosterone signals the kidneys to produce more erythropoietin, commonly called EPO. EPO is the hormone that tells the bone marrow to manufacture more red blood cells. Testosterone also increases the availability of iron, which feeds that manufacturing process. The result is secondary erythrocytosis: an elevated red cell count caused by an outside factor, in this case a hormone, rather than a bone marrow problem.
That distinction matters. Some patients search online and encounter the word polycythemia, which sounds alarming. Polycythemia vera is a bone marrow cancer that causes uncontrolled red cell overproduction. TRT-induced erythrocytosis is a different condition entirely. It is predictable, dose-related, and reversible. The two share a symptom, elevated hematocrit, but the mechanism, risk profile, and management are not the same. Knowing which one applies is part of what a proper evaluation establishes before testosterone replacement therapy begins.
Both the American Urological Association and the Endocrine Society use 54 percent as the intervention threshold for high hematocrit on testosterone. Above that number, the risk of erythrocytosis-related complications, including deep vein thrombosis and pulmonary embolism, rises in a way that requires clinical action.
Hoot HRT applies that threshold within a broader protocol. If a patient’s baseline hematocrit comes in above 50 percent before therapy starts, we work it up before prescribing. A baseline above 50 can point to untreated sleep apnea, dehydration at the time of draw, or another underlying condition that should be addressed first. Starting testosterone on top of an already-elevated hematocrit accelerates the risk without giving the patient or provider a stable baseline to work from.
Once therapy is underway, the 54 percent mark triggers a specific response: dose reduction, a change in formulation or injection frequency, or referral for therapeutic phlebotomy. The goal is not to chase a number. It is to keep hematocrit in a range where the benefits of optimized testosterone are not offset by the risks of thickened blood.
The monitoring schedule is not an afterthought. It is built into how Hoot HRT manages every patient from day one.
Hematocrit is drawn at baseline before any therapy begins. It is repeated at 6 weeks, which catches patients who respond quickly to testosterone. Then again at 6 months to confirm the trend. After that, hematocrit runs on the panel every six months unless something clinical warrants an earlier draw.
That schedule exists for a reason. The first six weeks on testosterone often produce the sharpest rise in hematocrit. A lab at that point catches early movers before they become a problem. The 6-month draw catches the slower responders. Semi-annual monitoring after that holds the baseline steady so a gradual upward drift does not go unnoticed between annual physicals.
Hematocrit does not run in isolation. The same panel includes estradiol, PSA, metabolic markers, and a complete blood count. A single number in isolation is less useful than the pattern across all of them. This is part of what distinguishes a monitored therapy program from a pharmacy-only model: results are reviewed by a provider, in context, every time.
Yes, and this is something most clinics do not explain before starting therapy.
Weekly or biweekly testosterone injections create a peak-and-trough pattern. Levels spike shortly after the injection and then fall before the next dose. Those peaks push testosterone concentrations well above the physiologic range for a day or two, and that spike is what drives the sharpest hematocrit rises. The higher and more frequent the peaks, the more the bone marrow is stimulated.
Smaller, more frequent injections smooth out those peaks. Testosterone creams and gels applied daily maintain steadier hormone levels throughout the week, which tends to produce a more modest effect on hematocrit. This is not a reason to avoid injections. It is a reason to think carefully about frequency, dose, and whether a formulation adjustment makes sense when hematocrit is trending upward.
Hoot HRT operates as a telehealth clinic, which means prescribing is limited to creams, gels, and injectable testosterone. That limitation is relevant here: some in-person clinics use pellet therapy, where a fixed dose is implanted under the skin for three to six months. If hematocrit rises after a pellet insertion, there is no dose to reduce until the pellet dissolves. With injectable or topical therapy, the response to an elevated hematocrit is immediate.
Testosterone is not the only driver. Several other factors push hematocrit in the same direction, and they matter because they can compound what TRT is already doing.
Sleep apnea is the most clinically significant one. When breathing repeatedly stops during sleep, oxygen levels drop, and the body responds by making more red blood cells to carry whatever oxygen is available. Hoot HRT screens patients for sleep apnea before starting therapy because an untreated case can make hematocrit management on TRT meaningfully harder. Treating the apnea sometimes lowers hematocrit on its own.
Smoking raises hematocrit through a similar oxygen-deprivation pathway. Dehydration at the time of the lab draw artificially concentrates the blood and can produce a reading that is higher than the patient’s true baseline. And doses that exceed what the patient actually needs will drive more erythrocytosis than a dose calibrated to symptoms and lab targets.
When a patient comes in with a baseline hematocrit above 50 and no obvious explanation, sleep apnea is the most productive place to look first. Treating it before starting testosterone sometimes normalizes the baseline on its own, which changes the risk profile of the whole conversation.
Reviewing how normal labs differ from optimal hormone health helps clarify why a single number in a reference range is not the full story, and why context and pattern matter more than any one value.
The TRAVERSE trial was a large, randomized controlled study published in 2023 in the New England Journal of Medicine that evaluated cardiovascular outcomes in men with hypogonadism on testosterone gel. It is the most rigorous cardiovascular safety data on TRT currently available.
The headline finding was reassuring: testosterone therapy did not increase the rate of heart attacks or strokes compared to placebo. That finding is real and it matters for how providers and patients think about the long-term risk profile of TRT.
What most summaries leave out is the rest of the data. The TRAVERSE trial also found higher rates of pulmonary embolism, atrial fibrillation, and acute kidney injury in the testosterone group compared to placebo. None of those are minor findings. Pulmonary embolism is a blood clot in the lungs. Atrial fibrillation is an irregular heart rhythm with its own stroke risk. Acute kidney injury indicates stress on renal function.
Being straight about these findings is not a reason to avoid testosterone therapy for appropriate patients. It is a reason to monitor it. The TRAVERSE data does not say TRT is dangerous for patients who are properly selected and properly followed. It says that proper follow-up is not optional. That standard is built into how Hoot HRT manages every patient from the first panel forward.
When hematocrit rises to a level that warrants a response, four approaches are commonly used, sometimes in combination.
Dose reduction is the first and simplest option. Less testosterone means less EPO stimulation and less red cell production. This usually brings hematocrit down within a few weeks, though the full effect takes closer to three months, which is how long a red blood cell lives before being replaced.
Changing delivery method or injection frequency addresses the peak-and-trough problem. A patient on weekly injections who moves to smaller twice-weekly doses, or transitions to a daily topical, may see hematocrit stabilize without any change in total hormone exposure.
Therapeutic phlebotomy, the clinical term for removing a unit of blood, produces a faster reduction. Hoot HRT refers patients for this when the clinical picture warrants it. It is not something to coordinate independently or repeat without clinical guidance. Each phlebotomy removes iron along with the red blood cells, and repeated sessions can deplete iron stores and cause fatigue. Iron and ferritin need to stay on the monitoring panel whenever phlebotomy is part of the plan.
Blood donation is sometimes framed as a convenient workaround. It carries the same iron depletion risk as phlebotomy and should be discussed with your clinician before starting, not used as a substitute for clinical oversight.
Treating underlying sleep apnea, when confirmed, can lower hematocrit meaningfully on its own. This is often the most productive intervention when apnea is present because it addresses a root cause rather than a lab value.
A few symptoms are worth reporting before the next scheduled draw: persistent headache, visual changes, facial flushing, or unexplained shortness of breath. These are not definitive signs of elevated hematocrit, but they are not symptoms to wait on.
Nothing extra.
At Hoot HRT, re-labs and dose adjustments are included in the membership at no additional charge. A clinician reply is guaranteed within one business day. If your hematocrit rises between draws, you do not wait for an annual appointment to find out what to do next.
The pricing page covers exactly what is included. Men and women throughout San Antonio, Austin, and across Texas can start with a complimentary consultation by telehealth. No referral, no office visit required.
Medical Review Byline: Medically reviewed by John M. Cash, MD, Co-Founder and Medical Director, Hoot HRT
Both the AUA and Endocrine Society identify 54 percent as the threshold that requires clinical action on testosterone therapy. Above that level, the risk of blood clots, pulmonary embolism, and other complications increases enough to warrant a dose adjustment, formulation change, or referral for phlebotomy. Hoot HRT acts at that threshold for every patient in Texas rather than waiting until symptoms appear.
Hoot HRT monitors hematocrit at baseline before therapy starts, again at 6 weeks, at 6 months, and then every 6 months for the duration of therapy. The 6-week draw catches patients who respond quickly to testosterone, while the 6-month draw confirms the trend before moving to semi-annual monitoring. This schedule is built into every Hoot HRT membership for men in San Antonio and across Texas.
Yes. Weekly or biweekly injections create peaks that push testosterone above physiologic range and drive stronger hematocrit responses. Daily creams and gels maintain steadier hormone levels and tend to produce a more modest effect on red cell counts. Hoot HRT prescribes injectable and topical testosterone through its telehealth model and adjusts delivery method when hematocrit is trending upward.
They are not in the same condition. Polycythemia vera is a bone marrow cancer that causes uncontrolled red cell overproduction and requires different treatment. TRT-induced erythrocytosis is a secondary elevation in red blood cells caused by testosterone’s effect on EPO production. It is predictable, reversible, and manageable with dose or formulation adjustments. Hoot HRT distinguishes between these two conditions as part of the evaluation process for every patient in Texas.
Blood donation can help lower hematocrit, but it carries the same iron depletion risk as therapeutic phlebotomy. Repeated donation without monitoring iron and ferritin levels can cause fatigue and iron deficiency, which works against the goals of testosterone therapy. Coordinate with your Hoot HRT clinician before using blood donation as part of a hematocrit management plan.
The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, found no increase in heart attacks or strokes with testosterone therapy compared to placebo. However, the same trial found higher rates of pulmonary embolism, atrial fibrillation, and acute kidney injury in the testosterone group. Hoot HRT reviews these findings with patients in Texas as part of informed consent before starting therapy.
If hematocrit reaches 54 percent or higher, Hoot HRT responds with one or more of the following: dose reduction, change in testosterone formulation or injection frequency, or referral for therapeutic phlebotomy. A clinician reply is guaranteed within one business day, and re-labs and adjustments are included in the membership at no extra charge. Men throughout San Antonio, Austin, and Texas receive this monitoring as a standard part of care.
DISCLAIMER
This article is for informational purposes only and does not constitute medical advice. Hormone therapy may not be appropriate for all patients. Individual results vary. Consult a qualified healthcare provider before making any decisions about testing or treatment.
SOURCES
